{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:11:23Z","timestamp":1769764283508,"version":"3.49.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Prostate cancer can significantly impact psychological, physical, and social well-being. This systematic review compares the development of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer (EORTC QLQ-PR25) for evaluating quality of life (QoL) in prostate cancer patients, focusing on development, characteristics, reliability, validity, and psychometric properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Thirteen studies published between 2013 and 2022\u00a0met the inclusion criteria. FACT-P and EORTC QLQ-PR25 are both validated, reliable, and responsive instruments for assessing QoL in prostate cancer patients. FACT-P emphasizes emotional, social, and functional well-being alongside prostate-specific concerns, while EORTC QLQ-PR25 focuses on prostate-specific symptoms, particularly urinary, sexual, and hormonal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The FACT-P and EORTC QLQ-PR25 are valid tools for assessing QoL in prostate cancer patients. The decision to use the FACT-P or the EORTC QLQ-PR25 instrument may depend on the population and aims of the proposed study. Given substantial advancements in treatment and patient care in prostate cancer since the initial development of the FACT-P and EORTC QLQ-PR25, these quality of life instruments should undergo comprehensive validation to ensure they remain a relevant and effective tool for contemporary prostate cancer clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/spc.0000000000000786","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:00:52Z","timestamp":1769709652000},"page":"33-44","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer \u2013 an updated literature review"],"prefix":"10.1097","volume":"20","author":[{"given":"David","family":"Chen","sequence":"first","affiliation":[{"name":"Princess Margaret Hospital Cancer Centre, Radiation Medicine Program, Toronto, Ontario, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Jomy","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital Cancer Centre, Radiation Medicine Program, Toronto, Ontario, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Ning","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Cheng","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira","family":"Khan","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bottomley","sequence":"additional","affiliation":[{"name":"Bottomley Consulting Group, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[{"name":"Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Chung","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin Fung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Emmenegger","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Hird","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Chow","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-3125","authenticated-orcid":false,"given":"Henry C. Y.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Princess Margaret Hospital, Kowloon West Cluster, Hospital Authority, Hong Kong S.A.R., China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Raman","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Radiation Oncology, BC Cancer, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"R1-20260129","first-page":"561\u2013568","article-title":"Prostate cancer: psychosocial implications and management","volume":"4","author":"Roth","year":"2008","journal-title":"Future Oncol Lond Engl"},{"key":"R2-20260129","doi-asserted-by":"crossref","first-page":"185\u2013195","DOI":"10.1007\/s11934-003-0068-1","article-title":"Quality of life after treatment for prostate cancer","volume":"4","author":"Penson","year":"2003","journal-title":"Curr Urol Rep"},{"key":"R3-20260129","doi-asserted-by":"crossref","first-page":"1358\u20131367","DOI":"10.1093\/jnci\/djh259","article-title":"Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study","volume":"96","author":"Potosky","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R4-20260129","doi-asserted-by":"crossref","first-page":"e0284727","DOI":"10.1371\/journal.pone.0284727","article-title":"Mental wellbeing and quality of life in prostate cancer (MIND-P): protocol for a multi-institutional prospective cohort study","volume":"18","author":"Brunckhorst","year":"2023","journal-title":"PLOS ONE"},{"key":"R5-20260129","doi-asserted-by":"crossref","first-page":"1095\u20131110","DOI":"10.1016\/j.ccell.2022.09.012","article-title":"Artificial intelligence for multimodal data integration in oncology","volume":"40","author":"Lipkova","year":"2022","journal-title":"Cancer Cell"},{"key":"R6-20260129","doi-asserted-by":"crossref","first-page":"95\u2013110","DOI":"10.1007\/s11764-021-01007-9","article-title":"Body image, self-esteem, and sense of masculinity in patients with prostate cancer: a qualitative meta-synthesis","volume":"16","author":"Bowie","year":"2022","journal-title":"J Cancer Surviv"},{"key":"R7-20260129","doi-asserted-by":"crossref","first-page":"327\u2013336","DOI":"10.3109\/07357909309024860","article-title":"Quality of life in cancer: definition, purpose, and method of measurement","volume":"11","author":"Cella","year":"1993","journal-title":"Cancer Invest"},{"key":"R8-20260129","doi-asserted-by":"crossref","first-page":"1078\u20131082","DOI":"10.1002\/1097-0142(19930201)71:3+<1078::AID-CNCR2820711429>3.0.CO;2-Z","article-title":"Expanding the definition of quality of life for prostate cancer","volume":"71","author":"Sharp","year":"1993","journal-title":"Cancer"},{"key":"R9-20260129","doi-asserted-by":"crossref","first-page":"17588359221141306","DOI":"10.1177\/17588359221141306","article-title":"Optimal assessment of quality of life for patients with prostate cancer","volume":"14","author":"Briggs","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"R10-20260129","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3346\/jkms.2006.21.2.295","article-title":"The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales in men with prostate cancer: reliability and validity of the Korean version","volume":"21","author":"Hong","year":"2006","journal-title":"J Korean Med Sci"},{"key":"R11-20260129","doi-asserted-by":"crossref","first-page":"2219\u20132230","DOI":"10.1007\/s11136-015-0958-y","article-title":"Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate\u2019s egg","volume":"24","author":"O\u2019Leary","year":"2015","journal-title":"Qual Life Res"},{"key":"R12-20260129","doi-asserted-by":"crossref","first-page":"523\u2013531","DOI":"10.2217\/cer.14.41","article-title":"Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients","volume":"3","author":"Chu","year":"2014","journal-title":"J Comp Eff Res"},{"key":"R13-20260129","doi-asserted-by":"crossref","first-page":"1132\u20131142","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"R14-20260129","doi-asserted-by":"crossref","first-page":"1695\u20131707","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"R15-20260129","first-page":"2418\u20132424","article-title":"An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"van Andel","year":"2008","journal-title":"Eur J Cancer Oxf Engl"},{"key":"R16-20260129","doi-asserted-by":"crossref","first-page":"920\u2013928","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"R17-20260129","doi-asserted-by":"crossref","first-page":"2777\u20132786","DOI":"10.1007\/s11136-013-0411-z","article-title":"Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials","volume":"22","author":"Robinson","year":"2013","journal-title":"Qual Life Res"},{"key":"R18-20260129","doi-asserted-by":"crossref","first-page":"527\u2013536","DOI":"10.2217\/fon-2017-0438","article-title":"Validating the Total Illness Burden Index for Prostate Cancer (TIBI-CaP) in Men with Castration-Resistant Prostate Cancer: Data from TRUMPET","volume":"14","author":"Flanders","year":"2018","journal-title":"Future Oncol"},{"key":"R19-20260129","doi-asserted-by":"crossref","first-page":"591\u2013598","DOI":"10.1007\/s11136-014-0794-5","article-title":"Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients","volume":"24","author":"Diels","year":"2015","journal-title":"Qual Life Res"},{"key":"R20-20260129","doi-asserted-by":"crossref","first-page":"238\u2013244","DOI":"10.1016\/j.jval.2013.12.005","article-title":"Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer","volume":"17","author":"Skaltsa","year":"2014","journal-title":"Value Health"},{"key":"R21-20260129","doi-asserted-by":"crossref","first-page":"977\u2013983","DOI":"10.1002\/pon.1817","article-title":"Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN\/FACT-P symptom index","volume":"20","author":"Victorson","year":"2011","journal-title":"Psychooncology"},{"key":"R22-20260129","doi-asserted-by":"crossref","first-page":"1877\u20131885","DOI":"10.1002\/cncr.31973","article-title":"Meaningful differences and validity for the NCCN\/FACT-P symptom index: an analysis of the ALSYMPCA data","volume":"125","author":"Beaumont","year":"2019","journal-title":"Cancer"},{"key":"R23-20260129","doi-asserted-by":"crossref","first-page":"1760\u20131767","DOI":"10.1007\/s13187-021-02024-z","article-title":"Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate\u2014FACT-P (Version 4) in prostate cancer patients","volume":"37","author":"De Held","year":"2022","journal-title":"J Cancer Educ"},{"key":"R24-20260129","doi-asserted-by":"crossref","first-page":"755\u2013763","DOI":"10.1007\/s11136-019-02316-4","article-title":"Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged \u2018no-problems\u2019","volume":"29","author":"Murasawa","year":"2020","journal-title":"Qual Life Res"},{"key":"R25-20260129","doi-asserted-by":"crossref","first-page":"2383\u20132391","DOI":"10.1007\/s11136-019-02184-y","article-title":"Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P","volume":"28","author":"Murasawa","year":"2019","journal-title":"Qual Life Res"},{"key":"R26-20260129","first-page":"2379\u20132393","article-title":"The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer","volume":"25","author":"Choi","year":"2016","journal-title":"Qual Life Res"},{"key":"R27-20260129","doi-asserted-by":"crossref","first-page":"2397\u20132402","DOI":"10.1007\/s11136-015-0993-8","article-title":"Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer","volume":"24","author":"Wong","year":"2015","journal-title":"Qual Life Res"},{"key":"R28-20260129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12955-018-0859-1","article-title":"The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation","volume":"16","author":"Umbehr","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"R29-20260129","doi-asserted-by":"crossref","first-page":"299\u2013305","DOI":"10.1159\/000355689","article-title":"Cross-cultural application of the Korean version of the European organization for research and treatment of cancer quality of life questionnaire for patients with prostate cancer - EORTC QLQ-PR25","volume":"85","author":"Park","year":"2013","journal-title":"Oncology"},{"key":"R30-20260129","doi-asserted-by":"crossref","first-page":"124\u2013129","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy\u2013Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"R31-20260129","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fonc.2019.00783","article-title":"The role of response-shift in studies assessing quality of life outcomes among cancer patients: a systematic review","volume":"9","author":"Ilie","year":"2019","journal-title":"Front Oncol"},{"key":"R32-20260129","doi-asserted-by":"crossref","first-page":"1281432","DOI":"10.3389\/fonc.2023.1281432","article-title":"Unraveling the safety of adjuvant radiotherapy in prostate cancer: impact of older age and hypofractionated regimens on acute and late toxicity - a multicenter comprehensive analysis","volume":"13","author":"Buwenge","year":"2023","journal-title":"Front Oncol"},{"key":"R33-20260129","doi-asserted-by":"crossref","first-page":"45\u201355","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"R34-20260129","doi-asserted-by":"crossref","first-page":"702\u2013715","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"R35-20260129","doi-asserted-by":"crossref","first-page":"125\u2013138","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"R36-20260129","doi-asserted-by":"crossref","first-page":"186\u2013195","DOI":"10.1158\/1055-9965.EPI-23-1034","article-title":"Trends of prostate cancer morbidity in low-incidence countries from 1990\u20132019","volume":"33","author":"Jiang","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R37-20260129","doi-asserted-by":"crossref","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"R38-20260129","doi-asserted-by":"crossref","first-page":"118\u2013126","DOI":"10.1002\/pros.24087","article-title":"Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality","volume":"81","author":"Shih","year":"2021","journal-title":"Prostate"},{"key":"R39-20260129","doi-asserted-by":"crossref","first-page":"1550\u20131558","DOI":"10.1002\/cncr.32692","article-title":"Development of the Functional Assessment of Cancer Therapy\u2013Immune Checkpoint Modulator (FACT-ICM): a toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs","volume":"126","author":"Hansen","year":"2020","journal-title":"Cancer"},{"key":"R40-20260129","doi-asserted-by":"crossref","first-page":"869\u2013872","DOI":"10.2967\/jnumed.122.264946","article-title":"Developing a patient-reported outcome measure for radionuclide therapy for prostate cancer","volume":"64","author":"Gudenkauf","year":"2023","journal-title":"J Nucl Med"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:00:58Z","timestamp":1769709658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000786","relation":{},"ISSN":["1751-4266"],"issn-type":[{"value":"1751-4266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}